Evercore ISI has upgraded Becton Dickinson & Co. (NYSE: BDX) to Outperform status and established a price target of $180. The firm reinstated coverage on the Life Sciences Diagnostics segment after a one-year pause due to its divestiture.
Strong Growth Prospects Amid Market Challenges
Analysts view the current fiscal year as a pivotal transition period for Becton Dickinson. Biosciences and Diagnostics segments demonstrate robust momentum, despite temporary headwinds from vaccines and analysis. Data reveals organic sales growth holding steady in the low single digits, attributed to timing rather than structural issues.
Excluding pandemic-related factors, Becton Dickinson maintains mid-single-digit growth trajectories. Over the past 12 months, sales increased by 6.22%, supporting a market capitalization around $42.51 billion.
China Market Adjustments and Tailwinds
Positive developments include resilience in Alaris, vaccines, and China’s volume-based procurement (VBP) system. China accounts for nearly 90% of sales, with ongoing VBP adjustments. CDC projections indicate a 25% decline in vaccine sales by fiscal 2026.
A 25% sales reduction could shift margins from 9-10% across segments, yielding approximately 250 basis points in overall profitability through six key areas. Tailwinds encompass GLP-1 drugs, novel animal health products, U.S. drug pricing reforms, tariffs, hospital monitoring, and more.
New Product Launches and Financial Updates
Becton Dickinson ranks as the median performer among 1,400 U.S. analyst-rated stocks based on proprietary risk-adjusted data. The company recently introduced the BD CentroVena One Insertion System, driving top-tier growth in central venous catheter sales by simplifying insertion procedures.
Additionally, Becton Dickinson declared a quarterly dividend of $1.05 per share, equating to an annual payout of $4.20. The ex-dividend date falls on June 9, 2026, with payment to shareholders of record on June 30, 2026.
The firm also secured CE Mark approval for the Liverty TIPS Stent Graft, enabling commercialization across the European Union. This device targets critical interventions for portal hypertension patients.
Analyst Perspectives
Argus adjusted its price target downward from $230 to $180 while retaining a Buy rating, citing concerns over medical and interventional segment risks.
Raymond James expressed caution on 2025 sales guidance, highlighting engineering uncertainties post prior growth periods. Investors should monitor these dynamics closely for informed decisions.
